Numab Therapeutics AG

Numab is pleased to announce a new collaboration and option agreement with Kaken Pharmaceutical to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD). Kaken has obtained an option to acquire commercial rights to ND081 for certain Asian territories in exchange for funding global development of ND081 up to clinical POC.  To learn more, please read our press release: https://lnkd.in/dm3aDvQN

Numab is pleased to announce the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeutic targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell receptor associated antigen CD3. The low molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers. To learn more, please read our press release: https://lnkd.in/duQpPrCa

We are happy to announce today that we have completed the acquisition of Yellow Jersey Therapeutics, a demerged subsidiary of Numab Therapeutics by Johnson & Johnson. With the acquisition, J&J secures the global rights to NM26, a novel, investigational first-in-class bispecific antibody for the therapy of atopic dermatitis, in an all-cash transaction of approximately USD 1.25 billion, as announced on May 28, 2024. https://lnkd.in/daWRtKVR This success was made possible first and foremost by an outstanding team of people at Numab Therapeutics. Thank you for your hard work and dedication to developing innovative therapies for patients in need! A big thank you goes to Kaken Pharmaceutical Co Ltd in Japan, for having been a visionary and loyal partner since the beginning of the NM26 program. We would also like to thank all our external partners who contributed with their tremendous development expertise to this achievement. On the transaction Numab was advised by Centerview Partners, Morgan Stanley, Baker McKenzie, Lars-Kristian Bråten, KPMG and other advisors.

Numab is thrilled to announce that Johnson & Johnson has entered into a definitive agreement to acquire Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab that holds the rights to NM26. NM26 is an investigational first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis, discovered and engineered through Numab’s proprietary MATCH™ technology platform.   Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally for atopic dermatitis and follow-on indications. This acquisition further validates our discovery and engineering platform and its potential to bring novel multi-specific antibodies to underserved patient populations.   To learn more, please read our press release: https://lnkd.in/daWRtKVR

We are delighted to welcome Mireia G. to Numab Therapeutics AG as a Chief Business Officer. Her insights as an accomplished biopharma executive and leader will be invaluable as we further advance the development of our broad and robust pipeline of multi-specific antibody-based immunotherapies.

We are excited to announce today that Numab and ONO PHARMACEUTICAL CO., LTD. entered a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers, identified through Numab’s proprietary discovery and engineering technology platform.   This collaboration with a leading pharma company further validates Numab’s unique plug-and-play antibody technology platform and demonstrates its ability to continue to generate exciting candidates for the treatment of cancer and inflammatory diseases.   To learn more, please read our press release:  https://lnkd.in/dfsii_J3